Skip to main content

Table 1 Patients characteristics and outcomes

From: Effects of dexamethasone on immune dysfunction and ventilator-associated pneumonia in COVID-19 acute respiratory distress syndrome: an observational study

 

Wave 1 (n = 18)

Wave 2 (n = 18)

P

Age—years

66 [61–70]

70 [61–73]

0.419

Male gender—n (%)

14 (78)

15 (83)

 > 0.99

Body mass index—kg/m2

31 [28–36]

31 [28–36]

0.567

Hypertension—n (%)

8 (44)

10 (56)

0.740

Diabetes—n (%)

5 (63)

9 (50)

0.310

SAPS II score—points

39 [33–50]

37 [31–47]

0.486

SOFA score at Day 1a—points

8 [6–9]

5 [2–8]

0.041

Delay between symptoms and ICU admission—days

6 [4–9]

9 [7–11]

0.09

Delay between ICU admission and intubation—days

1 [0–2]

1 [1, 2]

0.356

Bacterial superinfection at intubation—n (%)

6 (33)

3 (17)

0.440

Lowest PaO2/FiO2 ratio during ICU stay—mmHg

83 [62–112]

81 [62–100]

0.784

Severity of ARDS—n (%)

  

0.460

Moderate

6 (33)

4 (22)

 

Severe

12 (67)

14 (78)

 

Duration of invasive mechanical ventilation—days

29 [18–47]

12 [8–22]

 < 0.01

Ventilation acquired pneumoniae—n (%)

15 (83)

13 (72)

0.802

Delay between intubation and VAP—days

13 [8–27]

7 [5–11]

0.020

Day 28 mortality—n (%)

5 (28)

2 (11)

0.210

Day 90 mortality—n (%)

8 (44)

3 (17)

0.150

  1. SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, ARDS acute respiratory distress syndrome, VAP ventilation acquired pneumoniae. Results were compared using Mann–Whitney test or Fisher’s exact test, as appropriate
  2. aDay 1: day of the first measures of lymphocytes counts and monocyte HLA-DR expression
  3. Data are expressed as median (interquartile) and number (percentage)